EZMEKLY

This brand name is authorized in Austria, Estonia, Italy, Lithuania, Romania.

Active ingredients

The drug EZMEKLY contains one active pharmaceutical ingredient (API):

1	Mirdametinib UNII 86K0J5AK6M - MIRDAMETINIB
	Mirdametinib is a selective, non‑competitive inhibitor of mitogen‑activated protein kinase kinases 1 and 2 (MEK1/2). Mirdametinib blocks MEK activity and the rat sarcoma (RAS)‑rapidly accelerated fibrosarcoma (RAF)‑MEK pathway. Therefore, MEK inhibition blocks proliferation and survival of tumour cells in which the RAF‑MEK‑extracellular related kinase (ERK) pathway is activated.
	Read more about Mirdametinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EZMEKLY Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EE05		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EE Mitogen-activated protein kinase (MEK) inhibitors
Discover more medicines within L01EE05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3124224, 3124235, 3124246, 3124257, 3124268
IT	Agenzia del Farmaco	052398017, 052398029, 052398031, 052398043, 052398056
LT	Valstybinė vaistų kontrolės tarnyba	1104230, 1104231, 1104232, 1104233, 1104234
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W71401001, W71402001, W71402002, W71403001, W71403002